Ad Scientiam raises €5M in funding

We are delighted to welcome TechLife Capital as our new lead shareholder. This transaction marks a key milestone for Ad Scientiam, to strengthen our digital biomarkers portfolio, explore new therapeutic areas, and affirm our ambition to become the global leader in digital biomarkers.

For over 10 years, we have been putting medical and technological innovation at the service of patients and healthcare professionals, and we are more determined than ever to transform real-world monitoring of serious and disabling diseases.